Artificial intelligence (AI) is transforming the pharmaceutical industry, offering improvements in clinical trials and drug development while also posing significant security challenges. A recent report revealed that 64% of pharmaceutical executives are cautious about AI integration due to security concerns, especially as AI budgets are outstripping IT investments. To enable effective AI adoption, a proactive security-first approach is essential. This requires embedding data protection and compliance from the outset, as reactive strategies lead to vulnerabilities that can compromise trust and violate privacy laws. AI solutions must be designed collaboratively with security, privacy, and compliance teams to ensure robustness and transparency. Addressing interoperability and integration issues, alongside navigating complex global regulations, is crucial. The opportunity for AI in drug development is substantial; however, security must be foundational to foster innovation and protect sensitive patient data. Prioritizing these elements will pave the way for ethical and scalable advancements in the pharmaceutical sector.
Source link
Share
Read more